- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Evolving Immunotherapy in Myeloma: Insights on Bispecific and Trispecific Antibodies from ASCO 2025
A panelist discusses the most significant research findings on bispecific antibody therapy for relapsed/refractory multiple myeloma presented at ASCO 2025, highlighting breakthroughs and novel therapies that may shift treatment paradigms, assessing the clinical implications for improving patient management and outcomes, and exploring emerging trispecific therapies with potential to further transform future care.
EP. 1: Setting the Stage and New Milestones in Talquetamab Data
June 17th 2025A panelist discusses the latest advancements presented at ASCO 2025, highlighting talquetamab’s pivotal trial in relapsed/refractory multiple myeloma that demonstrated high response rates and longer durability with biweekly dosing, including in patients previously treated with B-cell maturation antigen–targeted therapies, supporting sequencing and combination strategies to improve outcomes.
Watch
EP. 2: Diving Deeper: Long-Term Safety With Talquetamab
June 24th 2025A panelist discusses recent advancements in bispecific antibody therapies for relapsed/refractory multiple myeloma, emphasizing the promising efficacy and improved safety profile of GPRC5D-targeting agents, the importance of patient-specific factors in therapy selection, and the role of prophylactic measures to manage infection risks, supporting personalized treatment strategies.
Watch
